Diabetic Macular Edema

Diabetic Macular Edema (DME) is a serious ocular complication of diabetes mellitus, affecting both type 1 and type 2 diabetes. It is a leading cause of adult-onset blindness globally.^[1] DME involves the accumulation of fluid within and beneath the macula, the central part of the retina responsible for sharp, detailed vision.^[1] This fluid buildup leads to swelling and distortion of the macula, significantly impairing central vision.^[1]DME can occur independently or alongside other forms of diabetic retinopathy (DR), such as non-proliferative (NPDR) or proliferative diabetic retinopathy (PDR).^[1]

Biological Basis

The biological foundation of DME involves damage to the retinal vasculature, a common feature of diabetic retinopathy. This damage can lead to the formation of microaneurysms and the leakage of fluid, lipids, and proteins into the retinal tissue, particularly in the macula.^[1] At a cellular level, multiple vascular and neural cell types of the retina are affected.^[1]While environmental factors like prolonged diabetes duration and poor glycemic control are significant, genetic factors also play a crucial role, with the heritable component of diabetic retinopathy estimated to be between 25% and 50%.^[1] Genome-wide association studies (GWAS) are employed to identify specific genetic variants that contribute to the risk and progression of complex diseases like DME.^[1] For instance, studies have explored candidate genes like MRPL19 and previously reported loci such as PCKS2 and MALRD1 in relation to DR and DME.^[1] Mitochondrial dysfunction has also been implicated as a potential underlying mechanism.^[1]

Clinical Relevance

The diagnosis of DME is based on clinical examination, often graded using recognized severity scales such as the ETDRS criteria.^[1]Key risk factors for developing DME include a longer duration of diabetes, inadequate glycemic control, hypertension, dyslipidemia, central obesity, smoking, and high blood pressure.^[1]Although significant advancements in treatment have been made, particularly with anti-VEGF therapies and fenofibrate, many patients continue to experience visual impairment.^[1]Understanding the genetic underpinnings through studies like GWAS can provide clearer insights into the biological pathways relevant to the disease, potentially leading to more effective personalized treatments.^[1]

Social Importance

DME represents a substantial public health challenge due to its high prevalence among individuals with diabetes. With an estimated 40.3% of diabetes patients experiencing some form of retinopathy and 8% specifically developing DME, its impact on visual health is considerable.^[1] As a leading cause of new cases of blindness in working-aged adults, DME significantly affects individual quality of life, independence, and economic productivity.^[1] The ongoing research into genetic risk factors and biological mechanisms is vital in the global effort to prevent blindness associated with diabetes and improve outcomes for affected individuals.^[1]

Methodological and Statistical Constraints

Genetic studies of complex traits like diabetic macular edema (DME) face inherent challenges related to study design and statistical power. Many genome-wide association studies (GWAS) for diabetic retinopathy (DR) phenotypes, including DME, have a limited ability to detect genetic variants with small effect sizes, which are common in complex diseases. This constraint means that even large cohorts may not be sufficient to identify very modest genetic effects, potentially leading to an underestimation of the genetic architecture of DME.^[1]Furthermore, the interpretation of small effect sizes can be challenging, particularly when minor alleles exhibit opposing effects for different genome-wide significant single nucleotide polymorphisms (SNPs) or when SNPs show pleiotropic effects, affecting multiple traits.^[2] Replication of findings across different studies is often difficult, with initial associations sometimes failing to confirm in independent cohorts.^[3] This lack of replication can stem from various factors, including underlying heterogeneity between discovery and replication cohorts, such as the inclusion of individuals with both type 1 and type 2 diabetes or differing ancestry groups.^[4] Moreover, issues like misclassification of participants due to limited DR ascertainment, inconsistent phenotyping, or the absence of a minimum duration of diabetes for control subjects can bias results towards the null, further complicating the identification of true genetic associations.^[5]The observed overlap where some participants have both proliferative diabetic retinopathy (PDR) and DME also suggests these phenotypes may not be entirely independent, affecting separate analyses and requiring larger cohorts and functional testing for clearer differentiation.^[1]

Generalizability and Phenotypic Heterogeneity

A significant limitation in understanding the genetic basis of diabetic macular edema is the restricted generalizability of findings across diverse populations. Many studies are conducted in cohorts primarily of European descent, meaning their results may not be directly transferable to other ethnic groups and necessitate further investigation in diverse populations.^[2] Genetic architecture can vary substantially between different ancestries, with minor allele frequencies and allelic effects potentially differing, which can contribute to the lack of trans-ethnic replication.^[3] This ethnic specificity highlights the need for broader representation to identify additional genetic variants and assess the transferability of established findings globally.

Phenotypic definitions and measurement inconsistencies also pose considerable challenges. Earlier studies often used composite phenotypes for sight-threatening DR, which may obscure distinct genetic factors for specific complications like DME.^[1] Although later studies have stratified into more homogeneous groups, difficulties with standardized DR classification and recruitment protocols across different centers can still lead to misclassification.^[3] The exclusion of genetic variants with low minor allele frequencies (e.g., < 0.5%) in GWAS means that potentially important rare variants associated with DME are often overlooked, suggesting that sequencing-based approaches may be more suitable for their discovery.^[2] Additionally, reliance on a single measure for variables like HbA1c, rather than repeated measures reflecting long-term glycemic control, can introduce imprecision in phenotype characterization.^[4]

Complex Etiology and Remaining Knowledge Gaps

Diabetic macular edema is a complex trait influenced by a combination of genetic and numerous non-genetic factors, making its genetic dissection challenging. Well-documented environmental and systemic risk factors, such as longer duration of diabetes, poor glycemic control, hypertension, dyslipidemia, central obesity, and smoking, play a significant role in ocular diabetic complications.^[1] While some studies attempt to minimize the confounding effects of these primary factors, the substantial contribution of non-genetic elements can dilute the detectable impact of genetic risk factors, making it difficult to isolate genetic signals.^[3] The heritable component of DR is estimated to be between 25-50%, yet candidate gene studies have often yielded inconsistent results, pointing to considerable missing heritability and the need for more comprehensive genetic approaches.^[1] Despite advances, significant knowledge gaps remain in fully understanding the genetic architecture of DME. The challenges in interpreting small effect sizes and the occurrence of pleiotropic effects for associated SNPs underscore the need to move beyond single SNP associations to consider broader genetic contexts, including genes, pathways, and polygenic risk scores for potential clinical utility.^[2] Future research would benefit from larger international collaborations to enhance statistical power, stricter case-control definitions (especially regarding duration of diabetes), and more refined phenotyping, such as incorporating optical coherence tomography for precise DME assessment.^[4] Ultimately, whole-genome sequencing may be necessary to uncover the role of very rare variants, particularly for individuals at the extreme ends of the DME phenotypic spectrum.^[4]

Variants

The genetic landscape of diabetic macular edema (DME) involves variants in genes that influence mitochondrial function and non-coding RNA regulation. Thers1990145 variant is located within the second intron of the MRPL19 gene, which encodes a mitochondrial ribosomal protein. These proteins are fundamental components of the mitochondrial ribosome, essential for synthesizing proteins within mitochondria, the primary energy-producing organelles of the cell.^[1]Mitochondrial health is critical for retinal function, and dysfunction in these organelles has been implicated in various eye conditions, including age-related macular degeneration.

The rs1990145 variant was identified as a top-ranked single nucleotide polymorphism (SNP) associated with DME in a genome-wide association study, suggesting its potential role in disease susceptibility.^[1] Given that MRPL19 is expressed in the retina, alterations caused by polymorphisms like rs1990145 may lead to mitochondrial dysfunction and associated eye pathology. This cellular stress could be particularly detrimental under conditions of diabetes and hyperglycemia, potentially unmasking subclinical phenotypes and contributing to the development or progression of DME. Other mitochondrial ribosomal protein genes, such as MRPL9, MRPL23, and MRPL39, have also been linked to similar conditions, highlighting a broader role for mitochondrial integrity in retinal health.^[1] Long intergenic non-coding RNAs (lincRNAs), such as LINC00343, are a class of non-protein-coding RNAs that play crucial regulatory roles in gene expression, chromatin organization, and various cellular processes, including those relevant to ocular health.^[2] While the specific mechanisms of LINC00343 in DME are still under investigation, lincRNAs are known to influence cellular responses to stress and inflammation, pathways highly relevant to the development and progression of diabetic complications. Similarly, RNA5SP38 is a pseudogene for 5S ribosomal RNA; while often considered non-functional gene copies, some pseudogenes can exert regulatory control over gene expression or act as microRNA sponges, potentially influencing cellular protein synthesis or stress responses relevant to diabetic complications.^[6] A variant like rs4771506 within such a region could subtly alter these regulatory functions, thereby contributing to susceptibility or progression of conditions like diabetic macular edema.

Key Variants

RS ID	Gene	Related Traits
rs1990145	MRPL19	acute myeloid leukemia diabetic macular edema
rs4771506	LINC00343 - RNA5SP38	diabetic macular edema

Defining Diabetic Macular Edema and its Context

Diabetic macular edema (DME) is a sight-threatening complication of diabetes mellitus, characterized by the build-up of fluid in and beneath the macula, the central part of the retina responsible for sharp, detailed vision . This fluid buildup directly impairs central vision, making DME a significant sight-threatening complication of diabetes mellitus and a leading cause of adult-onset blindness worldwide.^[1] The clinical presentation involves a spectrum of severity, which is assessed through thorough ophthalmological examination.^[1]While DME specifically impacts the macula, it can manifest independently or concurrently with other forms of diabetic retinopathy, such as non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR).^[1]The severity of DME is clinically graded using recognized scales, often based on the Early Treatment Diabetic Retinopathy Study (ETDRS) criteria, which categorize the extent of macular involvement and guide treatment decisions.^[1]These scales help standardize the assessment of disease progression and response to therapy.^[1]

Diagnostic Assessment and Measurement Approaches

Diagnosis and monitoring of diabetic macular edema rely on a combination of objective and subjective assessment methods. Clinical examination, including fundus examination performed by a board-certified ophthalmologist, is crucial for initial diagnosis and classification of retinopathy severity.^[3]These examinations often utilize internationally recognized scales, such as the International Clinical Diabetic Retinopathy Disease Severity Scale and those based on ETDRS criteria, which provide a standardized framework for grading DME and other diabetic retinopathy phenotypes from stereoscopic color fundus photographs.^[3]Optical Coherence Tomography (OCT), particularly spectral-domain OCT (SD-OCT), is a key objective measurement tool for quantifying macular edema. Macular thickness, typically measured as the average thickness within the outermost 6mm circle of the ETDRS grid, provides a precise, quantitative assessment of fluid accumulation.^[2]This method allows for detailed tracking of disease progression and treatment response, with careful quality control measures applied to imaging data to ensure accuracy.^[2] Beyond ocular assessments, systemic clinical measurements, including HbA1c levels, blood pressure, and renal function, are also routinely collected and provide important correlative data for understanding the overall diabetic status.^[1]

Phenotypic Heterogeneity and Clinical Correlations

Diabetic macular edema exhibits considerable phenotypic heterogeneity, as it can present as an isolated complication or coexist with other forms of diabetic retinopathy, such as non-proliferative or proliferative diabetic retinopathy.^[1]While there is a recognized overlap in patient cohorts with different retinopathy subtypes, with some individuals developing both DME and PDR, studies suggest that distinct underlying factors may contribute to these varying clinical phenotypes.^[1] This diversity underscores the importance of precise phenotypic characterization for both clinical management and genetic research, as more homogeneous groups allow for better analysis.^[1]Several well-established clinical factors are strongly correlated with the presence and severity of DME. Studies consistently show significant differences in the duration of diabetes, prevalence of hypertension, presence of nephropathy, and HbA1c levels between individuals with DME and control groups without retinopathy.^[1] These systemic risk factors are crucial prognostic indicators and highlight the multifactorial nature of DME development.^[1]Interestingly, while age and sex have been associated with other retinopathy forms, they were not found to be significantly associated with DME in certain populations studied.^[1]

Causes

Diabetic macular edema (DME) is a serious complication of diabetes mellitus, characterized by fluid accumulation in the macula, leading to impaired central vision. Its development is influenced by a complex interplay of genetic predispositions, systemic metabolic factors, lifestyle choices, and the molecular pathways affected by these interactions.

Genetic Susceptibility

Genetic factors play a significant role in determining an individual’s risk for developing diabetic retinopathy (DR) and its complications like DME, with family studies indicating a heritable component ranging from 25% to 50% products (AGER) and aldose reductase (AKR1B1) are candidate genes in this multifactorial etiology, suggesting roles for metabolic pathways and the accumulation of damaging end-products.^[6]Inflammation is another crucial component, with several genes linked to diabetic retinopathy mediating retinal cell damage through inflammatory processes. Elevated levels of various cytokines, including those associated with Th2 and Th17 cells, are observed in the vitreous fluid of patients with proliferative diabetic retinopathy, indicating a robust inflammatory response.^[4]

Genetic Susceptibility and Pathways

Genetic factors contribute significantly to an individual’s susceptibility to diabetic retinopathy and DME, as evidenced by familial clustering and ethnic differences in disease prevalence. Genome-wide association studies (GWAS) are instrumental in identifying specific genetic risk factors, providing insights into the complex genetic architecture of these conditions. For instance, previously reported loci likePCKS2 and MALRD1have shown supportive evidence of association with diabetic retinopathy in Caucasian populations.^[1]Specific genetic variants, such as certain single nucleotide polymorphisms (SNPs) likers6986616 and rs11749718 near the PCKS2 gene, have been identified as top-ranked associations with DME.^[1]Other genes implicated in diabetic retinopathy through GWAS includeTBC1D4 and UCHL3, along with genes involved in mediating retinal cell damage via inflammation, ciliopathy, or free-iron radicals, such as COMMD6, BBS5, and SH3BP4. Genes like LRP2 (encoding the multiligand receptor megalin) and ARL4Care associated with lipid metabolism, highlighting its relevance to retinopathy pathogenesis.^[3] The CFH and CFBgenes, related to the complement system, also show polymorphisms associated with retinopathy, and there is potential association with long intergenic non-coding RNAs.^[6]

Systemic Contributors and Disease Progression

Beyond specific retinal mechanisms, the progression of DME is profoundly influenced by systemic factors and disruptions in metabolic homeostasis. Key epidemiological risk factors include the duration of diabetes, chronic hyperglycemia, hypertension, and dyslipidemia. These systemic conditions create a pro-inflammatory and pro-oxidative environment that exacerbates retinal damage and contributes to the development and worsening of DME.^[6]Intensive therapy aimed at controlling diabetes has shown beneficial effects on retinopathy complications, underscoring the importance of systemic glycemic management. Furthermore, comorbidities such as nephropathy, often defined by microalbuminuria or worse, are associated with increased risk and severity of diabetic retinopathy. The tight regulation of blood glucose, blood pressure, and lipid levels is therefore critical in mitigating the systemic consequences that drive the progression of DME and other diabetic microvascular complications.^[1]

Vascular Dysfunction and Angiogenesis Signaling

Diabetic macular edema (DME) is characterized by a breakdown of the blood-retinal barrier and aberrant angiogenesis, driven by several interconnected signaling pathways. A key mediator is vascular endothelial growth factor (VEGF), which, upon receptor activation, triggers intracellular signaling cascades leading to increased vascular permeability and new blood vessel formation.^[1]Oxidative stress, often exacerbated by elevated glucose levels, plays a crucial role in dysregulating these processes; for instance,NADPH Oxidase 4 (NOX4) generates reactive oxygen species that can promote VEGFexpression and contribute to blood-retinal barrier dysfunction . Furthermore, the Wnt pathway, when aberrantly activated by oxidative stress, also contributes to diabetic retinopathy progression.^[7] These pathways are not isolated but exhibit significant crosstalk; for example, NADPH Oxidase 4 can mediate VEGF receptor 2-induced neovascularization, highlighting a hierarchical regulation where oxidative stress acts upstream of angiogenic signaling . The mitogen-activated protein kinase (MAPK) pathway, which includes p38 MAPK involved in cellular responses to stress and activated by reactive oxygen species, is implicated in processes influencing vascular integrity.^[8] Therapeutic strategies targeting VEGF signaling, such as anti-VEGF therapies, directly address this dysregulation to reduce fluid leakage and neovascularization, while agents like fenofibrate can exert salutary effects by inhibiting oxidative stress-mediated Wnt pathway activation.^[1]

Inflammatory and Immune Responses

Inflammation is a critical component in the pathogenesis of DME, involving complex signaling pathways and regulatory mechanisms. Elevated levels of various cytokines, including those associated with Th2 and Th17 cells, are found in the vitreous fluid of patients with proliferative diabetic retinopathy, indicating an active immune response.^[9]Systemic soluble tumor necrosis factor receptors 1 and 2 (_TNF_R1 and _TNF_R2) are also associated with the severity of diabetic retinopathy, suggesting the involvement ofTNF-alphasignaling in disease progression.^[10] The NF-kappaB signaling pathway is a central regulator of inflammatory gene expression and is implicated in DME; its activation can lead to the transcription of pro-inflammatory cytokines and adhesion molecules, further exacerbating vascular damage.^[11] Complement factors, such as those encoded by CFH and CFBgenes, have been associated with retinopathy in type 2 diabetic patients, highlighting the involvement of the complement system in the inflammatory cascade within the retina.^[12] These inflammatory pathways interact significantly with vascular dysfunction, creating a feedback loop where inflammation promotes vascular leakage and angiogenesis, and vice versa.

Metabolic Derangements and Cellular Stress

Chronic hyperglycemia, a hallmark of diabetes, initiates a cascade of metabolic dysregulations that contribute to DME. High glucose levels can lead to increased oxidative stress and also impact energy metabolism within retinal cells. The receptor for advanced glycation end products (RAGE), for example, has a polymorphism (-374 T/A) in its gene associated with diabetic nephropathy and retinopathy, indicating its role in mediating the damaging effects of advanced glycation end products formed under hyperglycemic conditions.^[13]Furthermore, glucose uptake and utilization pathways are critical for retinal health. A novel splice variant ofAS160 has been identified that regulates GLUT4translocation and glucose uptake in muscle cells, suggesting that similar mechanisms of metabolic regulation and flux control could be dysregulated in the retina, affecting cellular energy balance and contributing to disease.^[14]Impaired insulin signaling, potentially influenced by proteins like ubiquitin carboxyl-terminal hydrolase l3 (UCHL3), which promotes insulin signaling and adipogenesis, could also contribute to metabolic stress in retinal cells.^[15] These metabolic pathway dysregulations create an environment of cellular stress that drives the pathogenesis of DME.

Genetic Predisposition and Regulatory Control

Genetic factors play a significant role in an individual’s susceptibility to DME, influencing the regulation of various pathways at multiple levels. Genome-wide association studies (GWAS) have identified several genetic loci associated with diabetic retinopathy and DME, suggesting a genetic predisposition beyond glycemic control.^[1] For instance, genes such as PCKS2 and MALRD1have been implicated in diabetic retinopathy.^[1] Additionally, variants in genes like LRP2, which encodes the multiligand receptor megalin, are known to cause syndromes with ocular involvement, underscoring the importance of receptor-mediated endocytosis and related regulatory mechanisms in retinal health.^[16] Specific gene polymorphisms, such as those in ICAM1, PPARGC1A, and MTHFR, are associated with different phenotypes of diabetic retinopathy, indicating that subtle variations in gene regulation can modulate disease presentation and severity.^[17]These genetic variations can affect transcription factor regulation, protein modification, or post-translational processes, ultimately altering pathway activity. The cumulative effect of these genetic predispositions, combined with environmental factors like chronic hyperglycemia, leads to pathway dysregulation and contributes to the emergent properties of DME, such as persistent macular edema and vision loss. Understanding these genetic underpinnings is crucial for identifying novel therapeutic targets and developing personalized treatment strategies.

Clinical Relevance of Diabetic Macular Edema

Diabetic macular edema (DME) is a significant and potentially blinding complication of diabetes mellitus, representing a leading cause of adult-onset visual impairment globally.^[1] Understanding its underlying mechanisms, risk factors, and distinct characteristics is crucial for effective patient management and the prevention of vision loss. Genome-wide association studies (GWAS) contribute to this understanding by identifying genetic predispositions that can inform clinical practice, even if current findings require further validation.

Early Detection and Risk Stratification

The clinical relevance of identifying factors associated with DME lies in enhancing early detection and improving risk stratification for individuals with diabetes. While established clinical factors such as the duration of diabetes, hypertension, nephropathy, and HbA1c levels are recognized as significantly different between DME cases and controls, genetic insights offer a complementary layer to risk assessment.^[1] For instance, the identification of suggestive loci, such as rs1990145 within the MRPL19 gene, provides avenues for future research into genetic screening tools.^[1] Such genetic markers, once validated, could help identify high-risk individuals before overt symptoms develop, allowing for earlier and potentially more effective preventive strategies or closer monitoring.

Further, the detailed clinical evaluation and grading of DME based on recognized severity scales, such as ETDRS criteria, underscore the importance of precise diagnostic utility.^[1] Integrating genetic risk profiles with these clinical assessments could pave the way for more personalized medicine approaches, tailoring screening frequency and initial interventions to an individual’s specific risk of developing DME. This comprehensive risk stratification could optimize resource allocation and improve patient outcomes by targeting interventions to those most likely to benefit.

Informing Prognosis and Therapeutic Strategies

Insights into the genetic underpinnings of DME hold significant prognostic value, influencing predictions of disease progression, treatment response, and long-term visual implications. Although current treatments, including anti-VEGF therapies and fenofibrate, have advanced, many patients continue to experience visual impairment.^[1] Understanding the biological pathways implicated by genetic findings, such as the potential role of mitochondrial dysfunction associated with genes like MRPL19, MRPL9, MRPL23, and MRPL39, could lead to the development of novel therapeutic targets.^[1] Polymorphisms in genes like MRPL19, which is expressed in the retina, may contribute to eye pathology under hyperglycemic stress, providing clues for new drug development beyond existing anti-VEGF approaches.

Moreover, identifying genetic variants that predict a patient’s response to specific treatments could guide personalized therapeutic strategies. This would enable clinicians to select the most effective treatment for an individual, potentially avoiding ineffective therapies and reducing treatment burden and costs. Such prognostic markers could also provide a clearer understanding of the long-term course of DME, helping to manage patient expectations and implement proactive measures to preserve vision.

Understanding Disease Heterogeneity and Comorbidities

The clinical relevance of genetic studies in DME also extends to clarifying the complex interplay between DME and other diabetic complications, as well as recognizing its heterogeneous nature. Diabetic retinopathy encompasses various phenotypes, including non-proliferative (NPDR), proliferative (PDR), and DME, with considerable overlap observed in patient populations.^[1] The observation that many patients present with either DME or PDR, despite some having both, supports the hypothesis that distinct underlying factors may lead to these different clinical phenotypes.^[1]This distinction is crucial for accurate diagnosis and targeted treatment, as therapies may differ based on the specific retinopathy subtype.

Furthermore, DME is intrinsically linked to broader systemic comorbidities associated with type 2 diabetes, such as hypertension and nephropathy.^[1]Genetic research helps to unravel the shared or distinct biological pathways contributing to these overlapping conditions, providing a more holistic view of diabetes complications. By stratifying these sight-threatening phenotypes, studies help create more homogeneous groups for analysis, which is vital for identifying specific genetic contributions and developing precise interventions for each manifestation of diabetic retinopathy.^[1]

Frequently Asked Questions About Diabetic Macular Edema

These questions address the most important and specific aspects of diabetic macular edema based on current genetic research.

---

1. My parents have diabetes. Does that mean I’ll definitely get DME?

No, not necessarily. While genetic factors play a significant role, contributing 25-50% to the risk of diabetic retinopathy (which includes DME), it’s not a guarantee. Your lifestyle, like managing blood sugar and blood pressure, also strongly influences whether you develop DME.

2. My sibling has diabetes but no DME, why did I get it?

It’s common to see differences even within families. You and your sibling might have different genetic variations that affect your individual risk for DME, even if you both have diabetes. Plus, other factors like your unique health habits, blood pressure, or cholesterol levels can also play a part.

3. Could a DNA test help my doctor choose the best treatment for my DME?

Potentially, yes. Understanding your specific genetic makeup can provide insights into which biological pathways are most active in your DME. This information could eventually lead to more personalized and effective treatments tailored just for you, though this is still an area of active research.

4. I manage my blood sugar perfectly. Can I still get DME because of my genes?

Unfortunately, yes. While excellent blood sugar control significantly reduces your risk, genetic factors still contribute 25-50% to the likelihood of developing diabetic retinopathy, including DME. Your genes can make you more susceptible even with the best efforts, though consistent management remains crucial.

5. Does my family’s ethnic background affect my risk for DME differently?

Yes, it can. Many genetic studies on DME have focused on people of European descent, and genetic risk factors can vary significantly across different ethnic groups. Your ancestry might influence your specific risk and how certain genetic variations impact you, highlighting the need for more diverse research.

6. Does having type 1 vs. type 2 diabetes change my genetic risk for DME?

While DME can affect both type 1 and type 2 diabetes patients, there can be subtle differences in genetic risk factors between the two types. Research often studies these groups separately because their underlying genetic architecture might vary, influencing susceptibility to complications like DME.

7. Is there something in my DNA that makes my eyes more vulnerable to diabetes?

Yes, there are specific genetic variations that can make your eyes more susceptible to damage from diabetes, leading to DME. Researchers have identified candidate genes like MRPL19, PCKS2, and MALRD1 that are linked to this increased risk, affecting how your retinal cells respond to diabetes.

8. If DME runs in my family, what can I do to prevent it?

You can significantly reduce your risk by actively managing factors you control. This includes maintaining excellent glycemic control, keeping your blood pressure and cholesterol in check, and avoiding smoking. While you can’t change your genes, lifestyle choices are powerful in mitigating genetic predispositions.

9. Does anything besides my blood sugar control influence my DME risk?

Absolutely. Beyond blood sugar, your risk for DME is also influenced by other factors like high blood pressure, unhealthy cholesterol levels, central obesity, and smoking. These environmental and lifestyle elements interact with your genetic makeup to determine your overall susceptibility.

10. Does my blood sugar from years ago matter more than my recent numbers for DME?

Yes, long-term glycemic control is very important for DME risk. While current blood sugar levels matter, the cumulative effect of diabetes duration and historical poor control significantly contributes to the damage that can lead to DME. Consistent, long-term management is key.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Graham, P. S., et al. “Genome-wide association studies for diabetic macular edema and proliferative diabetic retinopathy.”BMC Med Genet, vol. 19, no. 1, 2018, p. 70.

[2] Gao, Xiaoran, et al. “Genome-wide association analyses identify 139 loci associated with macular thickness in the UK Biobank cohort.” Human Molecular Genetics, vol. 28, no. 8, 2019, pp. 1381–1392.

[3] Sheu, W. H., et al. “Genome-wide association study in a Chinese population with diabetic retinopathy.”Hum Mol Genet, vol. 22, no. 15, 2013, pp. 3174-3183.

[4] Pollack, S., et al. “Multiethnic Genome-wide Association Study of Diabetic Retinopathy using Liability Threshold Modeling of Duration of Diabetes and Glycemic Control.”Diabetes, vol. 67, no. 12, 2018, pp. 2707-2717.

[5] Holliday, Elizabeth G., et al. “Insights into the genetic architecture of early stage age-related macular degeneration: a genome-wide association study meta-analysis.”PLoS One, vol. 8, no. 1, 2013, e53830.

[6] Awata, T. et al. “A genome-wide association study for diabetic retinopathy in a Japanese population: potential association with a long intergenic non-coding RNA.”PLoS One, vol. 9, no. 10, 2014, p. e111115.

[7] Liu, Q., et al. “Salutary effect of fenofibrate on diabetic retinopathy via inhibiting oxidative stress-mediated Wnt pathway activation.”Invest Ophthalmol Vis Sci, vol. 55, 2014, p. E-Abstract 1027.

[8] Meng, W., et al. “A genome-wide association study suggests that MAPK14 is associated with diabetic foot ulcers.”Br J Dermatol, vol. 177, 2017, pp. 298–305.

[9] Takeuchi, M., et al. “Elevated levels of cytokines associated with Th2 and Th17 cells in vitreous fluid of proliferative diabetic retinopathy patients.”PLoS One, vol. 10, 2015, p. e0137358.

[10] Kuo, J. Z., et al. “Systemic soluble tumor necrosis factor receptors 1 and 2 are associated with severity of diabetic retinopathy in Hispanics.”Ophthalmology, vol. 119, 2012, pp. 1041–1046.

[11] de Bie, P., et al. “Characterization of COMMD protein-protein interactions in NF-kappaB signalling.” Biochem. J., vol. 398, 2006, pp. 63–71.

[12] Wang, J., et al. “Association of CFH and CFB gene polymorphisms with retinopathy in type 2 diabetic patients.”Mediators Inflamm, 2013, p. 748435.

[13] Lindholm, E., et al. “The -374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients.”Diabetologia, vol. 49, 2006, pp. 2745–2755.

[14] Baus, D., et al. “Identification of a novel AS160 splice variant that regulates GLUT4 translocation and glucose-uptake in rat muscle cells.”Cell. Signal., vol. 20, 2008, pp. 2237–2246.

[15] Suzuki, M., et al. “Ubiquitin carboxyl-terminal hydrolase l3 promotes insulin signaling and adipogenesis.”Endocrinology, vol. 150, 2009, pp. 5230–5239.

[16] Kantarci, S., et al. “Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes.” Nat. Genet., vol. 39, 2007, pp. 957–959.

[17] Simoes, M. J., et al. “Genetic variants in ICAM1, PPARGC1A and MTHFR are potentially associated with different phenotypes of diabetic retinopathy.”Ophthalmologica, vol. 232, 2014, pp. 156–162.